From a translation point of view, results from this work indicated that in ovarian cancer tumouroids, ET-1R blockade with macitentan significantly reverted ET-1 effects, inhibiting the invasive and metastatic potential of cancer cells. Here, EDN1 is linked to ovarian carcinoma.